Assessment of Treatment Satisfaction in Psoriasis

项目概要/摘要 斑块状银屑病的治疗方法在有效性和副作用方面差异很大。通常很难 在以患者为中心的共享决策过程中确定最佳治疗方案 临床医生和患者。 NIH 和其他利益相关者认为患者报告的结果（PRO）对于 支持以患者为中心的护理，因为 PRO 反映了患者的观点并提供了重要的 改善临床决策和护理服务的信息。 治疗满意度是一个关键的 PRO，代表患者对治疗过程和结果的体验 的治疗。患者对治疗的满意度至关重要，因为它影响患者的治疗- 相关行为，例如继续使用药物的可能性、使用药物的可能性 正确地进行治疗，并遵守规定的治疗方案。这些与治疗相关的行为反过来， 严重影响治疗结果的成功。 这项研究的总体目标是验证患者报告的皮肤科特异性治疗 满意度仪器（DermSat）。在这项研究中，我们计划实现两个目标。在目标 1 中，我们将验证 DermSat 用于纵向评估稳定型银屑病期间患者对银屑病治疗的满意度 和照明弹。我们还将确定 DermSat 是否具有良好的可靠性。我们将研究这个目标 前瞻性、观察性队列，并从南部不同的银屑病患者群体中招募 加利福尼亚州。 在目标 2 中，我们将确定 DermSat 是否可以预测药物依从性和治疗变化。 具体来说，我们将通过检查之间的关系来评估 DermSat 的预测有效性 DermSat 以及随后的依从性和治疗变化评估。具有优良的测量 预测有效性将使临床医生能够识别治疗不满意情况并尽早进行干预以尽量减少 牛皮癣的长期影响。 这项研究的成功完成将产生第一个有效且可靠的皮肤病学特异性 治疗满意度仪。研究结果将对未来的临床试验产生显着影响 设计。 DermSat 将满足在这两种疾病的研究中获取患者治疗经验的迫切需求 已批准和正在研究的皮肤病治疗方法。有效评估患者治疗满意度 还将有助于在临床实践中为临床医生和患者之间的共同决策提供信息，预测 治疗依从性，并提高长期治疗成功的可能性。

PROJECT SUMMARY / ABSTRACT Treatments for plaque psoriasis vary substantially in effectiveness and side effects. It is often difficult to determine the optimal treatment during a patient-centric, shared decision-making process between the clinician and patient. The NIH and other stakeholders consider patient-reported outcomes (PROs) crucial for the support of patient-centered care because PROs reflect the patients’ perspective and offer important information to improve clinical decision-making and care delivery. Treatment satisfaction is a key PRO that represents the patient’s experience with the process and outcome of the treatment. Patient satisfaction with their treatment is critical because it affects patients’ treatment- related behaviors, such as the likelihood of continuing to use their medication, to use the medication correctly, and to adhere to prescribed treatment regimens. These treatment-related behaviors, in turn, substantially impact the success of treatment outcomes. The overarching goal of this study is to validate a patient-reported, dermatology-specific treatment satisfaction instrument (DermSat). In this study, we plan to achieve two aims. In Aim 1, we will validate DermSat for longitudinal assessment of patient satisfaction with psoriasis treatments during stable psoriasis and flares. We will also determine if DermSat will confer good reliability. We will study this aim in a prospective, observational cohort and recruit from a diverse psoriasis patient population in southern California. In Aim 2, we will determine whether DermSat predicts medication adherence and treatment changes. Specifically, we will evaluate the predictive validity of DermSat by examining the relationship between DermSat and subsequent assessment of adherence and treatment changes. A measure with excellent predictive validity will enable clinicians to identify treatment dissatisfaction and intervene earlier to minimize the long-term impact of psoriasis. The successful completion of this research will lead to the first valid and reliable dermatology-specific treatment satisfaction instrument. The study findings will have a marked impact on future clinical trial design. DermSat will address the critical need to capture patients’ treatment experience in studies for both approved and investigative dermatological therapies. Valid assessment of patients’ treatment satisfaction will also help inform shared decision-making between clinicians and patients in clinical practice, predict treatment adherence, and improve the likelihood of long-term treatment success.